Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion

Lung Cancer

Volumn 51, Issue 2, 2006, Pages 217-223

  Tibaldi, C ^a,f   Bernardini, I ^a   Chella, A ^b   Russo, F ^a   Toma, G ^c   Tempestini, F ^c   Malventi, M ^d   Vasile, E ^a   Ambrosino, N ^b   Falcone, A ^a,e  

^a Division of Medical Oncology   (Italy)

^b Division of Pneumology   (Italy)

^c Division of Pneumology   (Italy)

^d Division of Radiology   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f UO Oncologia Medica   (Italy)

Author keywords

Gemcitabine; Lung cancer; NSCLC; Prolonged infusion

Indexed keywords

CISPLATIN; CORTICOSTEROID DERIVATIVE; FUROSEMIDE; GEMCITABINE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INFUSION RATE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 31344451913     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.10.013     Document Type: Article

References (21)

1. D.M. Parkin Global cancer statistics in the year 2000 Lancet Oncol 2 2001 533 543
2. J. Bunn-PA, and K. Kelly New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: a review of the literature and future directions Clin Cancer Res 4 1998 1087 1100
3. Non-small-cell Lung Cancer Collaborative Group Chemotherapy in non-small-cell lung cancer: a meta-analysis using up-dated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
4. T. Le Chevalier, D. Brisgand, and J.Y. Douillard Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a multicenter European trial including 612 patients J Clin Oncol 12 1994 360 367
5. L. Crinò, G.V. Scagliotti, and S. Ricci Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer: a randomized phase III study of the Italian lung cancer project J Clin Oncol 17 1999 3522 3530
6. P. Bonomi, K. Kim, and D. Fairclough Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of Eastern Cooperative Oncology Group trial J Clin Oncol 18 2000 623 631
7. K. Kubota, K. Watanabe, and H. Kunitoh Final results of a randomized phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 21 2002 296a
8. C. Gridelli, F. Perrone, and C. Gallo Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the Elderly study (MILES) phase III randomized trial JNCI 95 2003 362 372
9. D.G. Pfister, D.H. Johnson, and C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
10. J.L. Abbruzzese, R. Grunewald, and E.A. Weeks A phase I clinical, plasma and cellular pharmacology study of gemcitabine J Clin Oncol 9 1991 491 498
11. R. Grunewald, J.L. Abbruzzese, and P. Tarasoff saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine Cancer Chemother Pharmacol 27 1991 258 262
12. R. Grunewald, H. Kantarjan, and M.J. Keating Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine in leukaemia Cancer Res 50 1990 6823 6826
13. R. Brand, M. Capadano, and M. Tempero A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors Invest New Drugs 15 1997 331 341
14. 2/min) and cisplatin Cancer Chemother Pharmacol 50 2002 80 83
15. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
16. P. Therasse, G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 3 2000 205 216
17. E. Kaplan, and P. Meier Non-parametric estimation from incomplete observations J Am Stat Assoc 53 1993 1245 1252
18. I.E. Smith, E.R. O'Brien, and D.C. Talbot Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin J Clin Oncol 5 2001 1336 1343
19. A. Ceribelli, C. Gridelli, and F. De Marinis Prolonged gemcitabine infusion in advanced non-small-cell lung carcinoma Cancer 98 2003 337 343
20. M. Tempero, W. Plunkett, and V. Ruiz Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 2003 3402 3408
21. E. Cappuzzo, G. Scagliotti, and S. Novello A parallel randomized phase II trial evaluating standard versus prolonged infusion gemcitabine (G) as first-line treatment in advanced non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2003 2634a